ReviewFrontiers of medicine in China2010
The value of epigenetic markers in esophageal cancer.
Review in Frontiers of medicine in China, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- The roles of RNA NHeliyon · 2022Review
- Ex vivo drug sensitivity testing as a means for drug repurposing in esophageal adenocarcinoma.PloS one · 2018Article
- DNA methylation biomarkers for head and neck squamous cell carcinoma.Epigenetics · 2018Article
- Expression of methylation-modulated tumor-related genes in endoscopically resected early esophageal squamous neoplasia.Oncology letters · 2017Article
- Aloe-emodin suppresses esophageal cancer cell TE1 proliferation by inhibiting AKT and ERK phosphorylation.Oncology letters · 2016Article
- Correlations of Promoter Methylation in WIF-1, RASSF1A, and CDH13 Genes with the Risk and Prognosis of Esophageal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma.Clinical epigenetics · 2016Review
- Epigenetics in the Pathogenesis of Esophageal Adenocarcinoma.Clinical and translational science · 2015Article
- Genetic and Epigenetic Alterations in Barrett's Esophagus and Esophageal Adenocarcinoma.Gastroenterology clinics of North America · 2015Review
- p16 hypermethylation: a biomarker for increased esophageal cancer susceptibility in high incidence region of North East India.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel.Genes & cancer · 2015Article
- Temporal evolution in caveolin 1 methylation levels during human esophageal carcinogenesis.BMC cancer · 2014Article
- Epigenetic biomarkers in esophageal cancer.Cancer letters · 2014Review
- Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.Cancer · 2013Article
- MAL hypermethylation is a tissue-specific event that correlates with MAL mRNA expression in esophageal carcinoma.Scientific reports · 2013Article
- Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma.General thoracic and cardiovascular surgery · 2013Review
- Epigenetic regulation of the Wnt signaling inhibitor DACT2 in human hepatocellular carcinoma.Epigenetics · 2013Article
- Methylation of TFPI-2 is an early event of esophageal carcinogenesis.Epigenomics · 2012Article
- Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma.World journal of gastroenterology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Developing esophageal cancer is a multi-step process that begins with the accumulation of genetic and epigenetic alterations, and leads to the activation of oncogenes and the inactivation or loss of tumor suppressor genes (TSG). In addition to genetic alteration, epigenetic modifications, and in particular DNA methylation, are recognized as a common molecular alteration in human tumors. In esophageal cancer, aberrant methylation of promoter regions occurs not only in advanced cancer, but also in premalignant lesions. DNA methylation is related to survival time and sensitivity of chemoradiotherapy. This review is mainly focused on epigenetic changes in esophageal cancer and the value of early detection for patient prognosis, treatment choices, and potential targeting therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.